A. Stenzinger

S. Fröhling, M. Kriegsmann, A. Warth, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harmonization and Standardization of Panel-Based Tumor Mutational Burden (TMB) Measurement: Real-World Results and Recommendations of the QuIP Study.

S. Fröhling, M. Tiemann, W. Weichert, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Health Care Infrastructure for Financially Sustainable Clinical Genomics.

Jeffrey A. Golden, H. Rehm, A. Iafrate, 2016, The Journal of molecular diagnostics : JMD.

Expression of the novel protein PTPIP51 in rat liver: an immunohistochemical study

D. Schreiner, A. Stenzinger, M. Wimmer, 2007, Histochemistry and Cell Biology.

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder

A. Stenzinger, S. Duensing, M. Hohenfellner, 2021, Scientific Reports.

KRAS/GNAS‐testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound‐guided workup of suspected mucinous neoplasms of the pancreas

P. Schirmacher, A. Stenzinger, D. Kazdal, 2021, Genes, chromosomes & cancer.

PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma

A. Stenzinger, A. Paradowska, M. Wimmer, 2009, The Prostate.

Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma

C. Plass, A. Warth, W. Weichert, 2016, Epigenetics.

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.

A. Stenzinger, A. von Deimling, M. Preusser, 2012, Blood.

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

A. Stenzinger, Michael Thomas, F. Lasitschka, 2020, Trials.

Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma

S. Fröhling, D. Jäger, E. Schröck, 2020, Cold Spring Harbor molecular case studies.

Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, W. Weichert, P. Schirmacher, 2020, Lung cancer.

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.

M. Kriegsmann, P. Schirmacher, A. Stenzinger, 2020, Lung cancer.

Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients

A. Stenzinger, F. Klauschen, D. Seehofer, 2012, Annals of Surgical Oncology.

Incidental postmortem diagnosis of DIPNECH in a patient with previously unexplained 'asthma bronchiale'.

W. Weichert, A. Stenzinger, M. Dietel, 2010, Pathology, research and practice.

The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.

A. Stenzinger, H. Schlemmer, D. Bonekamp, 2019, European urology focus.

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

A. Stenzinger, M. Dietel, D. Merino, 2019, Genes, chromosomes & cancer.

Integrating proteomics into precision oncology

C. von Kalle, S. Fröhling, S. Wiemann, 2020, International journal of cancer.

Loss of SOX2 expression induces cell motility via vimentin up‐regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma

J. Debus, W. Weichert, A. Stenzinger, 2015, Molecular oncology.

Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.

A. Stenzinger, H. Schlemmer, D. Bonekamp, 2019, European urology focus.

Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer

M. Kloor, A. Warth, W. Weichert, 2015, The American journal of surgical pathology.

Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations.

M. Kriegsmann, R. Longuespée, A. Warth, 2018, Lung cancer.

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

M. Kloor, J. Cheville, M. Manns, 2020, Hepatology.

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

W. Weichert, A. Stenzinger, C. Denkert, 2010, The Journal of molecular diagnostics : JMD.

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment

W. Weichert, A. Stenzinger, V. Budach, 2011, Clinical Cancer Research.

Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model

A. Stenzinger, M. Golatta, F. Schuetz, 2017, Geburtshilfe und Frauenheilkunde.

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

M. Kriegsmann, J. Kriegsmann, R. Longuespée, 2021, Translational lung cancer research.

Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence.

W. Weichert, A. Stenzinger, V. Budach, 2015, European journal of cancer.

Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K–AKT pathway

W. Weichert, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast—implications for tumor biology and pathological diagnosis

M. Kriegsmann, W. Weichert, A. Stenzinger, 2015, Genes, chromosomes & cancer.

Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

A. Stenzinger, H. Schlemmer, D. Bonekamp, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model

W. Weichert, A. Stenzinger, U. Haberkorn, 2012, Radiation oncology.

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

A. Stenzinger, D. Kazdal, M. Schlesner, 2020, EBioMedicine.

Durvalumab in frail and elder patients with stage four NSCLC: Study protocol of the randomized phase II DURATION trial

A. Stenzinger, Michael Thomas, F. Lasitschka, 2019 .

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma

A. Warth, W. Weichert, A. Stenzinger, 2013, BMC Cancer.

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.

Mark Robson, A. Stenzinger, J. Reis-Filho, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR‐mutated lung cancer

A. Stenzinger, D. Heim, F. Klauschen, 2018, International journal of cancer.

Novel GATA6-FOXO1 Fusions in a Subset of Epithelioid Hemangioma

C. Antonescu, A. Stenzinger, M. Kirchner, 2020, Modern Pathology.

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer

A. Warth, W. Weichert, P. Schirmacher, 2013, British Journal of Cancer.

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma

A. Warth, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

Molecular driver alterations and their clinical relevance in cancer of unknown primary site

M. Kriegsmann, W. Weichert, A. Stenzinger, 2016, Oncotarget.

Das molekularpathologische Brevier: was heißt: „hybrid capture“,„anchored multiplex PCR“ und amplikonbasiert?

A. Stenzinger, U. Lehmann, 2022, Der Pathologe.

EWSR1/FUS-CREB Fusions Define a Distinctive Malignant Epithelioid Neoplasm with Predilection for Mesothelial-Lined Cavities

L. Voltaggio, C. Antonescu, A. Stenzinger, 2020, Modern Pathology.

Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays

W. Weichert, P. Schirmacher, A. Stenzinger, 2020, Genes, chromosomes & cancer.

Community-driven development of a modified progression-free survival ratio for precision oncology

S. Fröhling, D. Jäger, E. Schröck, 2019, ESMO Open.

PARP inhibition in prostate cancer

D. Jäger, A. Stenzinger, S. Duensing, 2020, Genes, chromosomes & cancer.

Blood BRAFV 600 E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

A. Stenzinger, M. Preusser, D. Capper, 2012 .

Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma

A. Stenzinger, J. Lennerz, P. Möller, 2014, Leukemia & lymphoma.

Automated sample preparation with SP3 for low‐input clinical proteomics

Jeroen Krijgsveld, Albrecht Stenzinger, Rémi Longuespée, 2019, bioRxiv.

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.

D. Jäger, P. Schirmacher, A. Stenzinger, 2021, Urologic oncology.

PARP inhibition in BRCA2-mutated prostate cancer.

D. Jäger, A. Stenzinger, D. Bonekamp, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN).

W. Weichert, A. Stenzinger, V. Budach, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Label-Free Enrichment and Molecular Characterization of Viable 1 Circulating Tumor Cells from Diagnostic Leukapheresis Products . 2 3 Running head : CTCs from DLA for culture and molecular analysis . 4 5

T. Fehm, A. Stenzinger, H. Neubauer, 2019 .

Accurate and efficient detection of gene fusions from RNA sequencing data

S. Fröhling, A. Stenzinger, B. Hutter, 2021, Genome research.

[Novel morphological and molecular aspects of lung cancer].

A. Warth, W. Weichert, A. Stenzinger, 2013, Der Pathologe.

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.

C. von Kalle, W. Weichert, P. Schirmacher, 2021, Cancer discovery.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

P. Schirmacher, A. Stenzinger, A. Krämer, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy

W. Weichert, A. Stenzinger, J. Debus, 2015, Radiation Oncology.

Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model

W. Weichert, A. Stenzinger, J. Debus, 2013, Strahlentherapie und Onkologie.

High nuclear poly‐(ADP‐ribose)‐polymerase expression is prognostic of improved survival in pancreatic cancer

A. Stenzinger, C. Denkert, M. Dietel, 2012, Histopathology.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

N. Girard, A. Stenzinger, C. Swanton, 2019 .

Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer

A. Warth, W. Weichert, P. Schirmacher, 2015, British Journal of Cancer.

Noncompaction myocardium in association with type Ib glycogen storage disease.

A. Warth, W. Weichert, P. Schirmacher, 2012, Pathology, research and practice.

RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?

C. Antonescu, A. Stenzinger, M. Andrulis, 2021, Genes, chromosomes & cancer.

Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.

M. Kloor, M. von Knebel Doeberitz, A. Stenzinger, 2020, Gastroenterology.

NTRK testing: First results of the QuiP‐EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA‐based NGS assays

W. Weichert, P. Schirmacher, A. Stenzinger, 2020, Genes, chromosomes & cancer.

SARS-CoV-2 infects cells of the human exocrine and endocrine pancreas and interferes with beta-cell function

A. Stenzinger, J. Gehrmann, P. MacDonald, 2020 .

Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing

P. Schirmacher, A. Stenzinger, T. Blum, 2019, Oncotarget.

Ataxia-telangiectasia–Mutated Protein Kinase Levels Stratify Patients With Pancreatic Adenocarcinoma Into Prognostic Subgroups With Loss Being a Strong Indicator of Poor Survival

A. Warth, W. Weichert, A. Stenzinger, 2015, Pancreas.

Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma

C. Antonescu, A. Stenzinger, B. Dickson, 2020, The American journal of surgical pathology.

Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1

A. Stenzinger, R. Eberhardt, C. Heussel, 2019, Virchows Archiv.

Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".

B. Taylor, A. Stenzinger, E. Collisson, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

David Bonekamp, Kortine Kleinheinz, Matthias Schlesner, 2018, Cancer discovery.

Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies

Nicole Pfarr, Volker Endris, Wilko Weichert, 2016, Genes, chromosomes & cancer.

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2019, International journal of cancer.

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

A. Stenzinger, R. Eeles, A. Wyatt, 2021, The journal of pathology. Clinical research.

Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research

W. Weichert, A. Stenzinger, C. Denkert, 2010, Virchows Archiv.

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma

W. Weichert, P. Schirmacher, A. Stenzinger, 2016, Medicine.

Survival of Patients with Oral Cavity Cancer in Germany

Stefan Listl, Bernd Holleczek, Hermann Brenner, 2013, PloS one.

The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma

D. Schreiner, A. Stenzinger, M. Wimmer, 2008, Journal of cellular and molecular medicine.

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

A. Stenzinger, J. Gehrmann, P. MacDonald, 2021, Nature Metabolism.

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.

A. Stenzinger, S. Peters, A. Passaro, 2020, Cancer cell.

SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report

P. Schirmacher, A. Stenzinger, A. Hartmann, 2021, Diagnostic Pathology.

Follicle‐stimulating hormone receptor expression in soft tissue sarcomas

A. Warth, W. Weichert, P. Schirmacher, 2013, Histopathology.

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

M. Kriegsmann, A. Warth, A. Stenzinger, 2021, BMC Cancer.

Down‐regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer

W. Weichert, A. Stenzinger, C. Denkert, 2012, Histopathology.

Sarcoma classification by DNA methylation profiling

David T. W. Jones, S. Fröhling, I. Petersen, 2021, Nature Communications.

Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations.

D. Aust, A. Stenzinger, Michael Thomas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

S. Fröhling, P. Schirmacher, A. Stenzinger, 2021, Genes, chromosomes & cancer.

Homologous recombination repair deficiency (HRD): From biology to clinical exploitation

A. Stenzinger, D. Gonzalez de Castro, 2021, Genes, chromosomes & cancer.

Genomic features of renal cell carcinoma with venous tumor thrombus

L. Trennheuser, R. Eils, D. Jäger, 2018, Scientific Reports.

Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance

Jan Budczies, Nicole Pfarr, Volker Endris, 2017, Genes, chromosomes & cancer.

Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.

G. Kristiansen, A. Stenzinger, M. Falkenstein, 2020, Urologic oncology.

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role

H Dienemann, A. Warth, H. Dienemann, 2014, British Journal of Cancer.

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype

A. Warth, H. Dienemann, W. Weichert, 2013, European Respiratory Journal.

Integrative genomic and transcriptomic analysis of leiomyosarcoma

Katharina I. Deeg, C. von Kalle, S. Fröhling, 2018, Nature Communications.

Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors

S. Fröhling, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Oncoimmunology.

The landscape of metastatic progression patterns across major human cancers

Carsten Denkert, Jan Budczies, Michael Bockmayr, 2014, Oncotarget.

Protein Tyrosine Phosphatase Interacting Protein 51 (PTPIP51) mRNA Expression and Localization and Its In Vitro Interacting Partner Protein Tyrosine Phosphatase 1B (PTP1B) in Human Placenta of the First, Second, and Third Trimester

A. Stenzinger, N. Baal, M. Wimmer, 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Expression of PTPIP51 during mouse eye development

D. Schreiner, A. Stenzinger, M. Wimmer, 2008, Histochemistry and Cell Biology.

Epidermal Growth Factor-, Transforming Growth Factor-β-, Retinoic Acid- and 1,25-Dihydroxyvitamin D3-Regulated Expression of the Novel Protein PTPIP51 in Keratinocytes

D. Schreiner, A. Stenzinger, H. Hofer, 2007, Cells Tissues Organs.

The novel protein PTPIP51 exhibits tissue- and cell-specific expression

A. Stenzinger, H. Hofer, M. Wimmer, 2004, Histochemistry and Cell Biology.

Revisiting the Role of p53 in Prostate Cancer

A. Stenzinger, S. Duensing, M. Hohenfellner, 2021, Prostate Cancer.

Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis: results from the Onconetwork Immuno-Oncology Consortium.

R. Gottimukkala, A. Stenzinger, J. L. Costa, 2021, The Journal of molecular diagnostics : JMD.

Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes.

A. Stenzinger, M. Ligtenberg, F. Haller, 2020, The Journal of molecular diagnostics : JMD.

Variant classification in precision oncology

Melanie Boerries, Olaf Neumann, Michael Thomas, 2019, International journal of cancer.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

D. Jäger, P. Schirmacher, A. Stenzinger, 2019, Cancer Immunology, Immunotherapy.

Optimizing panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, P. Schirmacher, A. Stenzinger, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients

A. Stenzinger, C. Marquette, J. Benzaquen, 2019, Cancers.

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2019, International journal of cancer.

Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2018, International journal of cancer.

Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Olaf Neumann, Michael Thomas, Jan Budczies, 2018, Translational lung cancer research.

Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.

A. Enk, S. Fröhling, P. Schirmacher, 2018, Pathology.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

M. Kloor, P. Schirmacher, A. Stenzinger, 2018, Oncoimmunology.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

S. Fröhling, P. Schirmacher, A. Stenzinger, 2017, Oncoimmunology.

Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival

Maristela L Onozato, S. Fröhling, A. Iafrate, 2016, Genes, chromosomes & cancer.

Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance

M. Kloor, M. von Knebel Doeberitz, A. Stenzinger, 2020, medRxiv.

Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications

W. Weichert, A. Stenzinger, 2017, Pathobiology.

Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas

M. Kloor, W. Weichert, A. Stenzinger, 2017, Modern Pathology.

Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology

M. Kloor, W. Weichert, P. Schirmacher, 2016, Genes, chromosomes & cancer.

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

Tim Holland-Letz, Andreas Trumpp, Tobias Bäuerle, 2013, Nature Biotechnology.

High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.

D. Jäger, P. Schirmacher, A. Stenzinger, 2020, Urologic oncology.

Mutations in BRCA2 and taxane resistance in prostate cancer

D. Jäger, P. Schirmacher, A. Stenzinger, 2017, Scientific Reports.

Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma

C. Plass, P. Schirmacher, A. Stenzinger, 2019, Hepatology.

Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

S. Fröhling, E. Schröck, W. Weichert, 2020, The Journal of clinical investigation.

Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas

A. Tanay, A. Warth, A. Stenzinger, 2018, International journal of cancer.

Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51.

D. Schreiner, A. Stenzinger, H. Hofer, 2009, International review of cell and molecular biology.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

C. von Kalle, S. Fröhling, R. Eils, 2019, Nature Communications.

Mutations in POLE and survival of colorectal cancer patients – link to disease stage and treatment

M. Kloor, H. Brenner, J. Chang-Claude, 2014, Cancer medicine.

Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm

W. Klapper, S. Goerdt, W. Weichert, 2014, Oncotarget.

Copy number changes of clinically actionable genes in melanoma, non‐small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases

Daniel Heim, Nicole Pfarr, Volker Endris, 2016, Genes, chromosomes & cancer.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

S. Loi, W. Weichert, A. Stenzinger, 2016, Oncotarget.

Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Lung cancer.

Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC

S. Fröhling, B. Obermayer, W. Weichert, 2020, International journal of cancer.

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

S. Fröhling, B. Obermayer, W. Weichert, 2019, bioRxiv.

Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.

M. Kriegsmann, R. Longuespée, A. Warth, 2018, Pathology, research and practice.

Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas

M. Kriegsmann, R. Longuespée, A. Warth, 2017, International journal of cancer.

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report

A. Warth, P. Schirmacher, A. Stenzinger, 2016, Diagnostic Pathology.

A. Stenzinger, D. Heim, F. Klauschen, 2015 .

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

P. Schirmacher, A. Stenzinger, J. Budczies, 2019, Cancers.

Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells

Linda Wordeman, Wilko Weichert, Albrecht Stenzinger, 2014, Nature Cell Biology.

Gö-VIP-03: Prof. Dr. Holger Bastians Abteilung Molekulare Onkologie, UMG Originalpublikation: “Increased microtubule assembly rates influence chromosomal instability in colorectal cancer.” In: Nature Cell Biology. in press (DOI: 10.1038/ncb2994). Autoren:

A. Stenzinger, A. Aigner, L. Wordeman, 2014 .

Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α4–Integrin Deficient NOD Mouse

A. Stenzinger, T. Papayannopoulou, N. Müller, 2020, Cells.

Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer.

A. Warth, W. Weichert, A. Stenzinger, 2012, Human pathology.

Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness

A. Stenzinger, F. Klauschen, C. Stephan, 2011, Pathobiology.

Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing

S. Fröhling, A. Stenzinger, D. Hübschmann, 2020, Cancers.

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

D. Jäger, A. Stenzinger, M. Schlesner, 2017, Oncotarget.

Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.

A. Stenzinger, J. Budczies, Mingchao Xie, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression

A. Stenzinger, S. Pullamsetti, R. Savai, 2021, Cancers.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance

S. Fröhling, R. Eils, E. Schröck, 2019, Cold Spring Harbor molecular case studies.

Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix

W. Weichert, A. Stenzinger, M. Mollenhauer, 2018, Modern Pathology.

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

A. Stenzinger, E. Van Cutsem, T. Seufferlein, 2021, Cancers.

Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.

W. Weichert, P. Schirmacher, A. Stenzinger, 2019, Pathology.

Knowledge bases and software support for variant interpretation in precision oncology

S. Fröhling, R. Eils, D. Jäger, 2021, Briefings Bioinform..

Artificial Intelligence and Pathology: from Principles to Practice and Future Applications in Histomorphology and Molecular Profiling.

K. Müller, F. Tacke, M. Alber, 2021, Seminars in cancer biology.

Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary

W. Weichert, P. Schirmacher, A. Stenzinger, 2020, International journal of cancer.

Molecular dissection of large cell carcinomas of the lung with null immunophenotype.

M. Kriegsmann, A. Warth, P. Schirmacher, 2018, Pathology.

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome

P. Schirmacher, A. Stenzinger, A. Krämer, 2019, International journal of cancer.

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification

C. von Kalle, S. Fröhling, D. Jäger, 2016, Cold Spring Harbor molecular case studies.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders

H. Goldschmidt, A. Stenzinger, M. Andrulis, 2018, Leukemia & lymphoma.

Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature

David C. Jones, S. Fröhling, M. Ladanyi, 2021, Modern Pathology.

Germline SDHB‐inactivating mutation in gastric spindle cell sarcoma

S. Fröhling, E. Schröck, A. Stenzinger, 2020, Genes, chromosomes & cancer.

Three molecular pathways model colorectal carcinogenesis in Lynch syndrome

M. Kloor, M. von Knebel Doeberitz, A. Stenzinger, 2018, International journal of cancer.

Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management

S. Fröhling, A. Stenzinger, A. Buck, 2021, Frontiers in Endocrinology.

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer

Michael Thomas, Cleo-Aron Weis, Claus Peter Heussel, 2020, Cancers.

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

M. Kriegsmann, A. Stenzinger, K. Samitas, 2021, ESMO open.

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response

R. Eils, D. Jäger, A. Trumpp, 2017, Clinical Cancer Research.

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

A. Stenzinger, M. Faehling, A. Volckmar, 2017, Oncotarget.

Potential clinical implications of BRAF mutations in histiocytic proliferations

A. Stenzinger, J. Lennerz, T. Barth, 2014, Oncotarget.

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma

Wilko Weichert, Arne Warth, Albrecht Stenzinger, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway

Christopher R. Schmidt, C. Plass, A. Warth, 2014, Hepatology.

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Michael Thomas, Jan Budczies, Wilko Weichert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

W. Weichert, A. Stenzinger, Michael Thomas, 2020, Lung cancer.

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

M. Kriegsmann, P. Schirmacher, A. Stenzinger, 2021, Therapeutic advances in medical oncology.

EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial

P. Schirmacher, A. Stenzinger, M. Dietel, 2017, Virchows Archiv.

Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers

P. Hufnagl, P. Hufnagl, A. Stenzinger, 2014, International journal of cancer.

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma

C. von Kalle, S. Fröhling, R. Eils, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomisch-histologische Analyse eines „cancer of unknown primary“

S. Fröhling, A. Stenzinger, S. Gröschel, 2017, Forum.

Endometrial stromal sarcomas with BCOR‐rearrangement harbor MDM2 amplifications

David T. W. Jones, S. Fröhling, A. Stenzinger, 2020, The journal of pathology. Clinical research.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

T. Fehm, A. Stenzinger, N. Stoecklein, 2019, Clinical chemistry.

Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations

S. Fröhling, A. Stenzinger, B. Brors, 2021, Journal of translational medicine.

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS

A. Stenzinger, H. Schlemmer, D. Bonekamp, 2019, PloS one.

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types

P. Schirmacher, A. Stenzinger, C. Denkert, 2017, BMC Medical Genomics.

Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains

C. von Kalle, S. Fröhling, W. Weichert, 2019, Oncogene.

p53 partial loss-of-function mutations sensitize to chemotherapy

A. Stenzinger, D. Kazdal, O. Timofeev, 2021, Oncogene.

Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets

A. Stenzinger, D. Kazdal, S. Peters, 2021, Cell.

Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux.

A. Stenzinger, M. Zeitlinger, F. Andreoni, 2017, International journal of antimicrobial agents.

PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ.

A. Stenzinger, A. Paradowska, M. Wimmer, 2011, Histology and histopathology.

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

H. Kauczor, M. Kriegsmann, A. Stenzinger, 2020, Cancers.

Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin

W. Weichert, A. Stenzinger, C. Denkert, 2012, PloS one.

Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.

W. Weichert, A. Stenzinger, V. Budach, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

A. Hofman, S. Cajal, P. Brousset, 2020, ESMO Open.

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients

T. Holland-Letz, A. Schneeweiss, A. Trumpp, 2014, Oncotarget.

A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications

P. Schirmacher, A. Stenzinger, T. Fioretos, 2018, Genes, chromosomes & cancer.

Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology

W. Weichert, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.

Volker Endris, Wilko Weichert, Arne Warth, 2013, The Journal of molecular diagnostics : JMD.

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

A. Jauch, A. Stenzinger, A. Krämer, 2016, Blood.

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

A. Warth, W. Weichert, P. Schirmacher, 2014, Modern Pathology.

The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability

T. Beißbarth, W. Weichert, G. Braus, 2016, Oncogene.

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis

A. Stenzinger, M. Schlesner, H. Sültmann, 2021, npj Precision Oncology.

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

A. Stenzinger, J. Ficker, W. Brueckl, 2021, Translational lung cancer research.

Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma

P. Schirmacher, A. Stenzinger, R. Penzel, 2018, International journal of cancer.

PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor

A. Stenzinger, A. Bräuninger, A. Paradowska, 2015, Journal of Neuro-Oncology.

[Molecular diagnostics of non-small cell lung cancer: New markers and technologies].

M. Kriegsmann, A. Warth, W. Weichert, 2015, Der Pathologe.

Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes

A. Stenzinger, D. Kazdal, U. Haberkorn, 2019, The Journal of Nuclear Medicine.

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.

S. Fröhling, A. Stenzinger, R. Schlenk, 2021, ESMO Open.

Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease.

S. Fröhling, D. Jäger, E. Schröck, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

N. Halama, D. Jäger, A. Stenzinger, 2017, BMC Cancer.

Unmasked: when a clinically malignant disease turns out infectious. A rare case of tularemia.

W. Weichert, A. Stenzinger, R. Penzel, 2013, International journal of surgical pathology.

Precision oncology: a clinical and patient perspective.

A. Stenzinger, L. Makaroff, A. Italiano, 2021, Future oncology.

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

W. Weichert, A. Stenzinger, C. Denkert, 2010, Human pathology.

MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer

A. Stenzinger, J. Hong, P. Christopoulos, 2021, Journal of Thoracic Oncology.

Optimizing panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, P. Schirmacher, A. Stenzinger, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study

A. Stenzinger, F. Klauschen, D. Seehofer, 2014, Surgery Today.

Nivolumab maintenance after salvage autologous stem cell transplantation results in long‐term remission in multiple relapsed primary CNS lymphoma

S. Fröhling, A. Stenzinger, B. Hutter, 2018, European journal of haematology.

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

W. Weichert, A. Stenzinger, Michael Thomas, 2021, Lung cancer.

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model

W. Weichert, A. Stenzinger, U. Haberkorn, 2012, Radiation oncology.

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Translational lung cancer research.

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer

A. Stenzinger, M. Schlesner, Michael Thomas, 2019, Cold Spring Harbor molecular case studies.

Defining molecular risk in ALK+ NSCLC

A. Stenzinger, J. Budczies, H. Sültmann, 2019, Oncotarget.

EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer

A. Warth, P. Schirmacher, A. Stenzinger, 2018, International journal of cancer.

High‐throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

A. Warth, H. Dienemann, W. Weichert, 2016, Genes, chromosomes & cancer.

High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer.

W. Weichert, A. Stenzinger, M. Dietel, 2012, Human pathology.

Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

Daniel Heim, Peter Hufnagl, Carsten Denkert, 2012, Scientific Reports.

Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.

S. Fröhling, L. Levin, D. Gisselsson, 2021, Seminars in cancer biology.

N. Girard, A. Stenzinger, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary neoplasms of the parapharyngeal space: diagnostic and therapeutic pearls and pitfalls

A. Stenzinger, U. Borner, R. Giger, 2021, European Archives of Oto-Rhino-Laryngology.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy

S. Fröhling, A. Stenzinger, J. Fletcher, 2019, Molecular Cancer Therapeutics.

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma *

S. Fröhling, S. Ugurel, D. Aust, 2021, The British journal of dermatology.

DNA Index as a Strong Prognostic Factor in Patients With Adenocarcinoma of the Pancreatic Head: Results of a 5-Year Prospective Study

A. Stenzinger, F. Klauschen, D. Seehofer, 2013, Pancreas.

Cancer of Unknown Primary: The Pathologist’s Approach

W. Weichert, A. Stenzinger, 2016 .

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial

Michael Hummel, Ulrich Lehmann, Nicole Pfarr, 2016, Virchows Archiv.

Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA‐binding protein 3 in non‐small‐cell lung cancer

M. Kriegsmann, A. Warth, P. Schirmacher, 2020, Histopathology.

Die Rolle der Pathologie in der Diagnostik des CUP-Syndroms

W. Weichert, A. Stenzinger, M. Kriegsmann, 2014, Der Radiologe.

RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours

A. Rosenwald, M. Kriegsmann, P. Schirmacher, 2019, Gut.

Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks.

A. Stenzinger, J. Lennerz, M. Vogeser, 2021, Clinical chemistry.

Morphological and molecular breast cancer profiling through explainable machine learning

Masaru Ishii, Klaus-Robert Müller, Daniel Heim, 2021, Nature Machine Intelligence.

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

S. Fröhling, D. Jäger, P. Schirmacher, 2020, Cell Death & Disease.

cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data

Budczies Jan, Daniel Kosztyla, Christian von Törne, 2014 .

MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.

W. Weichert, A. Stenzinger, V. Budach, 2017, European journal of cancer.

KIT mutations in primary mediastinal B-cell lymphoma

W. Weichert, A. Stenzinger, J. Lennerz, 2014, Blood Cancer Journal.

10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

W. Weichert, A. Stenzinger, C. Denkert, 2017 .

The landscape of chromothripsis across adult cancer types

S. Fröhling, E. Schröck, A. Stenzinger, 2020, Nature Communications.

Mutations in genes encoding PI3K‐AKT and MAPK signaling define anogenital papillary hidradenoma

A. Warth, W. Weichert, A. Stenzinger, 2016, Genes, chromosomes & cancer.

[Impact of the novel in vitro diagnostic regulation (IVDR) of the European Union on pathology laboratories. What's important?]

W. Weichert, A. Stenzinger, 2020, Der Pathologe.

Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer

G. Kristiansen, W. Weichert, A. Stenzinger, 2013, Digestion.

Next-generation sequencing: hype and hope for development of personalized radiation therapy?

W. Weichert, A. Stenzinger, V. Budach, 2015, Radiation oncology.

Quantitative analysis of diagnostic guidelines for HER2-status assessment.

A. Warth, W. Weichert, A. Stenzinger, 2012, The Journal of molecular diagnostics : JMD.

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing

D. Aust, P. Schirmacher, A. Stenzinger, 2021, Virchows Archiv.

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making.

A. Warth, W. Weichert, P. Schirmacher, 2015, Lung cancer.

Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.

Melanie Boerries, Mario Lamping, Damian T. Rieke, 2018, JCO precision oncology.

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.

C. von Kalle, S. Fröhling, R. Eils, 2017 .

Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary.

A. Stenzinger, S. Delorme, T. Hielscher, 2021, European journal of cancer.

The combinatorial complexity of cancer precision medicine

Ulrich Keilholz, Frederick Klauschen, Manfred Dietel, 2014, Oncoscience.

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

A. Enk, A. Stenzinger, A. Dimitrakopoulou-Strauss, 2021, Cancers.

Digital PCR After MALDI–Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma

R. Casadonte, M. Kriegsmann, J. Kriegsmann, 2018, Proteomics. Clinical applications.

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information

R. Casadonte, M. Kriegsmann, J. Kriegsmann, 2018, Proteomics. Clinical applications.

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway

S. Fröhling, V. Glutsch, A. Rosenwald, 2021, The British journal of dermatology.

Immuno‐oncology gene expression profiling of formalin‐fixed and paraffin‐embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing

P. Schirmacher, A. Stenzinger, D. Kazdal, 2020, Genes, chromosomes & cancer.

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Case Reports in Oncology.

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, ESMO open.

Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer.

A. Stenzinger, T. Kuder, H. Schlemmer, 2021, European journal of radiology.

Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma

S. Fröhling, T. Luedde, S. Loosen, 2020, Case Reports in Gastroenterology.

Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays

Mark Kriegsmann, Arne Warth, Albrecht Stenzinger, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study

P. Schirmacher, A. Stenzinger, R. Penzel, 2018, Genes, chromosomes & cancer.

Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate

A. Stenzinger, T. Kuder, H. Schlemmer, 2018, European Radiology.

Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.

Manuel Wiesenfarth, Sebastian Bickelhaupt, David Bonekamp, 2019, Radiology.

Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions

A. Stenzinger, T. Kuder, H. Schlemmer, 2020, Investigative radiology.

Fully Automatic Deep Learning in Bi-institutional Prostate Magnetic Resonance Imaging

A. Stenzinger, T. Kuder, H. Schlemmer, 2021, Investigative radiology.

CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

S. Fröhling, A. Schneeweiss, D. Jäger, 2021, JCO precision oncology.

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines

W. Weichert, A. Stenzinger, A. Affolter, 2017, Head & neck.

KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma

W. Weichert, A. Stenzinger, C. Denkert, 2014, Pancreas.

Allelic ratio of KRAS mutations in pancreatic cancer.

A. Stenzinger, J. Lennerz, 2015, The oncologist.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.

A. Stenzinger, M. Roethke, H. Schlemmer, 2020, European urology focus.

Automated sample preparation with SP3 for low‐input clinical proteomics

Jeroen Krijgsveld, Albrecht Stenzinger, Rémi Longuespée, 2020, Molecular systems biology.

Histological tumor typing in the age of molecular profiling.

Daniel Heim, Frederick Klauschen, Albrecht Stenzinger, 2015, Pathology, research and practice.

Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed

W. Weichert, A. Stenzinger, J. Werner, 2016, Pancreas.

Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach

A. Warth, P. Schirmacher, A. Stenzinger, 2012, Virchows Archiv.

Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.

P. Schirmacher, A. Stenzinger, R. Penzel, 2017, Pathology.

ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases

A. Warth, H. Dienemann, W. Weichert, 2014, Histopathology.

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer

J. Debus, A. Stenzinger, D. Kazdal, 2021, ESMO open.

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

A. Stenzinger, Michael Thomas, J. Krisam, 2021, BMC cancer.

Genomics of Immunotherapy-Associated Hyperprogressors—Letter

Peter Horak, Stefan Fröhling, Albrecht Stenzinger, 2017, Clinical Cancer Research.

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer

M. Kriegsmann, A. Warth, W. Weichert, 2017, British Journal of Cancer.

Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility

M. Kriegsmann, A. Warth, P. Schirmacher, 2018, Genes, chromosomes & cancer.

The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients.

M. Kloor, M. von Knebel Doeberitz, D. Bishop, 2021, Gastroenterology.

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment

Carsten Denkert, Jan Budczies, Nicole Pfarr, 2016, Oncotarget.

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

H. Goldschmidt, A. Stenzinger, A. Benner, 2020 .

GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma

A. Stenzinger, J. Lennerz, P. Möller, 2015, Oncotarget.

Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment

W. Weichert, A. Stenzinger, F. Klauschen, 2012, Virchows Archiv.

Expression profile of PTPIP51 in mouse brain

A. Stenzinger, M. Wimmer, K. Steger, 2009, The Journal of comparative neurology.

FGFR2 Inhibition in Cholangiocarcinoma.

A. Stenzinger, A. Vogel, O. Segatto, 2022, Annual review of medicine.

Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study

W. Weichert, A. Stenzinger, F. Klauschen, 2014, European Archives of Oto-Rhino-Laryngology.

Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study

Jakob Nikolas Kather, R. Maron, M. Weichenthal, 2021, Journal of medical Internet research.

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy

W. Weichert, A. Stenzinger, J. Debus, 2015, Radiation oncology.

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

A. Warth, A. Stenzinger, U. Klingmüller, 2020, Translational lung cancer research.

Establishment of a patient-derived orthotopic osteosarcoma mouse model

W. Weichert, A. Stenzinger, H. Witt, 2015, Journal of Translational Medicine.

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

S. Fröhling, A. Stenzinger, R. Schlenk, 2020, EJHaem.

Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer

A. Stenzinger, C. Heussel, F. Herth, 2018, Annals of Oncology.

Genetic changes of non-small cell lung cancer under neoadjuvant therapy

Nicole Pfarr, Volker Endris, Wilko Weichert, 2016, Oncotarget.

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

David C. Jones, G. Reifenberger, A. Stenzinger, 2021, Acta Neuropathologica.

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

W. Weichert, P. Schirmacher, A. Stenzinger, 2019, Cancer Immunology, Immunotherapy.

Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?

Wilko Weichert, Arne Warth, Albrecht Stenzinger, 2015, Virchows Archiv.

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

A. Stenzinger, J. Gehrmann, P. MacDonald, 2021, Nature Metabolism.

Prolyl Hydroxylase Domain 2 Protein Is a Strong Prognostic Marker in Human Gastric Cancer

W. Weichert, A. Stenzinger, M. Dietel, 2012, Pathobiology.

Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma

A. Warth, H. Dienemann, W. Weichert, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PARP inhibition in BRCA2-mutated prostate cancer.

D. Jäger, A. Stenzinger, D. Bonekamp, 2017 .

Integrative genomic and transcriptomic analysis of leiomyosarcoma

Roland Eils, Kortine Kleinheinz, Matthias Schlesner, 2018, Nature Communications.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

Roland Eils, David Bonekamp, Kortine Kleinheinz, 2019, Nature Communications.

Molekulare Diagnostik in der Pathologie

W. Weichert, A. Stenzinger, R. Penzel, 2013, Deutsche Medizinische Wochenschrift.

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

W. Weichert, A. Stenzinger, V. Budach, 2015, Journal of Translational Medicine.

Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium

E. Schröck, W. Weichert, A. Stenzinger, 2019, Annals of Oncology.